Epigenetics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 16.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Epigenetics Market Analysis
The epigenetics market is projected to register a CAGR of 16.1% during the forecast period (2022-2027).
Covid has significantly impacted the epigenetics market growth due to the importance of epigenetics in COVID-19 research. For instance, according to the study published in Clinical Epigenetics, titled 'The epigenetic implication in coronavirus infection and therapy' in October 2020, epigenetic alterations might play an essential role in the onset of coronavirus disease complications. Although numerous treatment options are being investigated, further research is urgently needed to discover a viable vaccine or safer chemotherapeutic medications, including epigenetic therapies, to combat this viral pandemic and create pre-and post-exposure COVID-19 prophylaxis. This will lead to increased adoption of epigenetics in discovering therapies for COVID-19 infection, thereby expected to drive the market growth over the forecast period.
Factors such as the rising prevalence of cancers, rise in funding in research and development in healthcare, and rising applications of non-oncological applications of epigenetics, among others, are expected to drive the market growth over the forecast period.
As per Globocan 2020, there were 19,292,789 new cancer cases were reported worldwide. This worldwide and extensive cancer threat remains a major driver for developing new cancer therapies that help in risk assessment, early diagnosis, and effective treatment monitoring.
In addition, rising healthcare research and development expenditure across the globe is further expected to drive the growth of this market over the forecast period. For instance, according to the World Health Organization in December 2021, the gross domestic research and development expenditure on health (health GERD) as a percentage of gross domestic product (GDP) in high-income countries is 0.21%. For upper middle and low-income countries, it is 0.02%. Such huge investments in healthcare research and development will drive market growth due to adopting epigenetics in research.
On the other hand, the high cost of epigenetics and the dearth of skilled professionals in epigenetic research is expected to hamper the market studied.
Epigenetics Market Trends
This section covers the major market trends shaping the Epigenetics Market according to our research experts:
DNA Methylation is Expected to Hold a Major Share Over the Forecast Period
DNA Methylation segment is expected to hold a major share in the market studied over the forecast period. DNA methylation dominated the epigenetics market, as it is the covalent addition of a methyl group in the cytosine ring, which leads to the inhibition of transcription. Sensitive bisulfite modification, followed by PCR, is called methylation-sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods, such as allele-specific bisulfite sequencing, southern-based method, bisulfite pyrosequencing, and bisulfite PCR followed by MALDI - TOF MS, are also useful for DNA methylation. Technological advancements are increasingly enabling the assessment of locus-specific DNA methylation on a genome-wide scale, thereby driving market growth.
Fundraising by the DNA methylation start-up companies is expected to drive the market growth further. For instance, in June 2020, Base Genomics, an epigenetics firm, emerged from stealth with a team of outstanding scientists and an oversubscribed seed investment round of USD 11 million USD (GBP 9 million) to further its DNA methylation technology development. Oxford Sciences Innovation led the investment round, which included investors with experience in genomics and cancer. This will lead to increased research on DNA methylation, which will further lead to the adoption of reagents, kits, and instruments for DNA methylation, driving the market growth.
In February 2021, Twist Bioscience Corporation launched the Twist NGS Methylation Detection System, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome. This will further lead to increased adoption of DNA methylation to study the human genome for research and develop novel therapies, thereby expected to drive this segment growth.
Therefore, due to the abovementioned factors, the segment is expected to drive over the forecast period.
North America Holds a Major Share in the Epigenetics Market Over the Forecast Period
The factors owing to the growth include rapid developments in healthcare infrastructure, the presence of major regional players, huge investments in research and development, and the rising prevalence of cancers, among others. With increasing investments in the research and development of products by industries, the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines, are produced industrially. There is also growing demand for the development of cancer therapies in the United States, and a lot of investments are made in understanding cancer genomics, thereby expected to drive the growth of this market in North America. For instance, according to the United States National Institute of Health, in December 2021, the funding for cancer genomics was USD 1,098 million in 2020. The funding is expected to reach USD 1,152 million in 2022. The rise in funding in the United States on cancer genomics will lead to increased adoption of epigenetics in research, thereby expected to drive the market growth over the forecast period.
In addition, the rising prevalence of cancer is; also boosting the market growth in the region. For Instance, in the American Cancer Society (ACS), an estimated 1,918,030 new cases of cancer are expected for the year 2022 in the United States. Such a high burden of cancer creates the need for better diagnostics and therapeutics and hence it is expected to drive the market's growth due to the adoption of epigenetics in cancer research.
Moreover, rising investments by the market players in the United States for developing epigenetics are further expected to drive the growth of the market studied in this region. For instance, in November 2021, Chroma Medicine, Inc. (Chroma), a new genomic medicine company pioneering epigenetic editing, launched with USD 125 million in financing to address a wide range of diseases and become the technology of choice for gene regulation.
Therefore, due to the abovementioned factors, the market is expected to grow over the forecast period.
Epigenetics Industry Overview
The epigenetics market is moderately competitive. Major players in the market are focusing on expanding their epigenetics portfolio by fundraising and investing huge capital in research and development through acquisitions of and collaborations with other companies. The epigenetics market is expected to open up several opportunities for the new entrants and the currently established leading players. Some major players in this market include Abcam PLC, Active Motiff, Hologic Inc (Diagenode Inc.), F. Hoffmann-La Roche Ltd, Illumina Inc., and Qiagen NV, among others.
Epigenetics Market Leaders
-
Abcam PLC
-
Active Motiff
-
Illumina Inc.
-
Diagenode Inc.
-
Merck KGaA
*Disclaimer: Major Players sorted in no particular order
Epigenetics Market News
- In February 2022, Zenith Epigenetics Ltd. reported the dosing of the first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb's PD-1 immune checkpoint inhibitor OPDIVO and YERVOY in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.
- In February 2022, Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, entered a partnership with Dovetail Genomics to demonstrate the value and performance of Dovetail's proximity ligation-based-based next-generation sequencing (NGS) library prep solutions on Element's AVITI System.
Epigenetics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Defiinition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence and Prevalence of Cancer
- 4.2.2 Increasing Funding for R&D in Healthcare
- 4.2.3 Rising Epigenetic Applications in Non-oncology Diseases
-
4.3 Market Restraints
- 4.3.1 Rising Costs of Instruments
- 4.3.2 Dearth of Skilled Researchers
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product
- 5.1.1 Instruments
- 5.1.2 Reagents & Kits
- 5.1.3 Others
-
5.2 By Application
- 5.2.1 Oncology
- 5.2.2 Autoimmune Diseases
- 5.2.3 Metabolic Diseases
- 5.2.4 CNS/Pain Diseases
- 5.2.5 Cardiovascular Diseases
- 5.2.6 Others
-
5.3 By Technology
- 5.3.1 Methylation
- 5.3.2 Acetylation
- 5.3.3 Phosphorylation
- 5.3.4 Other Technologies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abcam PLC
- 6.1.2 Active Motiff
- 6.1.3 Hologic Inc (Diagenode Inc.)
- 6.1.4 F. Hoffmann-La Roche Ltd
- 6.1.5 Illumina Inc.
- 6.1.6 Merck & Co. Inc.
- 6.1.7 Qiagen NV
- 6.1.8 Thermo Fisher Scientific
- 6.1.9 Zymo Research Corporation
- 6.1.10 Perkin Elmer
- 6.1.11 Bio-Rad Laboratories
- 6.1.12 New England Biolabs
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityEpigenetics Industry Segmentation
As per the scope of this report, epigenetics, in simple terms, refers to the study of genetic effects that are not entirely encoded by the DNA sequence of an organism. Epigenetics mainly deals with gene expression. Epigenetics also refers to changes in the genome in terms of functionality, which do not involve changes in the nucleotide sequence. DNA methylation or histone modification is a mechanism that causes epigenetic changes. The Epigenetics Market is segmented by Product (Instruments, Kits, and Reagents, Others), Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases), Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Product | Instruments | |
| Reagents & Kits | ||
| Others | ||
| By Application | Oncology | |
| Autoimmune Diseases | ||
| Metabolic Diseases | ||
| CNS/Pain Diseases | ||
| Cardiovascular Diseases | ||
| Others | ||
| By Technology | Methylation | |
| Acetylation | ||
| Phosphorylation | ||
| Other Technologies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Epigenetics Market Research FAQs
What is the current Global Epigenetics Market size?
The Global Epigenetics Market is projected to register a CAGR of 16.10% during the forecast period (2024-2029)
Who are the key players in Global Epigenetics Market?
Abcam PLC, Active Motiff, Illumina Inc., Diagenode Inc. and Merck KGaA are the major companies operating in the Global Epigenetics Market.
Which is the fastest growing region in Global Epigenetics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Epigenetics Market?
In 2024, the North America accounts for the largest market share in Global Epigenetics Market.
What years does this Global Epigenetics Market cover?
The report covers the Global Epigenetics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Epigenetics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Epigenetics Industry Report
Statistics for the 2024 Epigenetics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Epigenetics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
